Clinical Research Directory
Browse clinical research sites, groups, and studies.
Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
Sponsor: Fundación para la Investigación del Hospital Clínico de Valencia
Summary
The goal of this clinical trial is to assess the efficacy of a pharmacogenetics-guided treatment, compared to standard optimized treatment, in patients with inadequately controlled type 2 diabetes. The main questions it aims to answer are: * Is the disease better controlled when the treatment prescribed is based on the participant's pharmacogenetic profile? * What medical problems do participants experience while taking the treatment? Participants will: * Take the treatment described according to the Summary of Product Characteristics (SmPC). * Visit the clinic once every 12 weeks for checkups and tests. * Keep a diary of their symptoms to inform the Investigator.
Official title: Open-label, Double-arm, Controlled, Randomized, Multicentre Clinical Trial to Evaluate the Impact of Pharmacogenetic-guided Treatment in Patients With Insufficiently Controlled Type 2 Diabetes.
Key Details
Gender
All
Age Range
40 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
504
Start Date
2025-05-26
Completion Date
2026-06-30
Last Updated
2026-02-23
Healthy Volunteers
No
Conditions
Interventions
Metformin
Metformin maximum daily dose 2000 mg
Dulaglutide
Dulaglutide
Semaglutide 1.0 mg
Semaglutide
Empagliflozin (BI 10773)
Empagliflozin
Canagliflozin
Canagliflozin
Dapagliflozin
Dapagliflozin
pioglitazone
Pioglitazone
Sitagliptin
Sitagliptin
Vildagliptin (Galvus)
vildagliptin
linagliptin
linagliptin
Locations (3)
Hospital Universitario Regional de Málaga
Málaga, Spain
Hospital Clínico Universitario de Valencia
Valencia, Spain
Hospital General Universitario de Valencia (HGUV)
Valencia, Spain